Skip to Content
Morningstar

CRISPR Therapeutics AG CRSP

Morningstar Rating
Unlock
Stock XNAS Rating as of
$55.66 +0.61 (1.11%)
View Full Chart
As of Delayed Price Pre-Open: $55.12 −0.53
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Positive Outlook for Crispr Therapeutics Thanks to Blockbuster Potential of Casgevy

Rachel Elfman

Crispr Therapeutics is a clinical-stage gene editing company focused on the development of CRISPR/Cas9-based therapeutics. The company's proprietary platform specializes in Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9, which precisely cuts DNA to disrupt, delete, correct, and insert genes to treat genetically defined diseases. CRISPR’s emerging technology has led to a new class of therapies, which are well suited for targeting rare diseases or other disorders that are caused by genetic mutations.

Read Full Report

Price vs Fair Value

View History
CRSP is trading within a range we consider fairly valued.
Price
$55.68
Fair Value
$725.00
Uncertainty
Very High
1-Star Price
$513.82
5-Star Price
$86.90
Economic Moat
Wsxsd
Capital Allocation
Byycwlkw

Bulls Say, Bears Say

Bulls

Partnerships allow Crispr Therapeutics to receive milestones and economic benefits from drug candidate progression while offsetting some of the clinical development costs.

Bears

Crispr Therapeutics’ pipeline is largely in the early stages of development and years away from potentially receiving approval.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CRSP is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$55.05
Day Range
$54.37–56.93
52-Week Range
$37.55–91.10
Bid/Ask
$53.70 / $59.00
Market Cap
$4.72 Bil
Volume/Avg
14 / 1.8 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
12.02
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Core
Total Number of Employees
407
Website
https://www.crisprtx.com

Competitors

Valuation

View More
Metric
CRSP
BNTX
VRTX
Price/Earnings (Normalized)
 —27.1726.27
Price/Book Value
 2.390.925.86
Price/Sales
 12.025.0610.55
Price/Cash Flow
 ——27.39
Price/Earnings
CRSP
BNTX
VRTX

Financial Strength

Metric
CRSP
BNTX
VRTX
Quick Ratio
 17.419.123.60
Current Ratio
 17.549.433.99
Interest Coverage
 ——86.38
Quick Ratio
CRSP
BNTX
VRTX

Profitability

Metric
CRSP
BNTX
VRTX
Return on Assets (Normalized)
 −3.61%3.43%19.46%
Return on Equity (Normalized)
 −4.34%3.85%25.47%
Return on Invested Capital (Normalized)
 −3.83%2.43%21.34%
Return on Assets
CRSP
BNTX
VRTX
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRMpnrzckpfqCwqc$557.8 Bil
VRTX
Vertex Pharmaceuticals IncVkyndgxdbRxytf$103.3 Bil
REGN
Regeneron Pharmaceuticals IncGyhbqrmmNpygww$98.8 Bil
MRNA
Moderna IncCkkbyxqrCqbf$38.8 Bil
ARGX
argenx SE ADRLhskwndFxnw$21.3 Bil
BNTX
BioNTech SE ADRKxbyptbfBbsc$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncCccjwchDzgykn$18.4 Bil
BMRN
Biomarin Pharmaceutical IncMfqxpnbxNksrhlq$17.0 Bil
RPRX
Royalty Pharma PLC Class ABjphgfypdLcjmcc$12.4 Bil
INCY
Incyte CorpZlpjxsvwzRlpsgm$11.9 Bil

Sponsor Center